CLEVELAND — Fifteen months. That is the average survival time for a patient diagnosed with glioblastoma. Surgery, radiation, chemotherapy — standard care buys less than a year and a half.
The real killer is the blood-brain barrier. It keeps toxins out of the brain, yes.
It also keeps medicine out. For decades, that has been the hard stop. A new study published in the journal Oncoscience offers a different path.
The compound is nitrosylcobalamin, or NO-Cbl. It is vitamin B12, chemically altered to release nitric oxide.
The idea is simple: trick the barrier, deliver the payload. Joseph A. Bauer of Nitric Oxide Services, LLC and the Cleveland Clinic Foundation Taussig Cancer Center led the work.
The team ran the compound through three tests. First, the NCI-60 human tumor cell line panel — a standard screen for activity against cancer cells. Second, pharmacokinetic studies in rats with glioblastoma tumors.
Third, tests combining NO-Cbl with other treatments on human glioblastoma cell lines. The results showed antitumor activity across a wide range of cancer types.
Central nervous system tumor cells showed moderate sensitivity. That matters. Few drugs even reach those cells alive.
Glioblastoma is not a rare disease. It is the most common malignant brain tumor in adults.
It is also the most aggressive. Standard treatment has not changed meaningfully in two decades. Temozolomide, the chemotherapy drug used now, extends survival by about two and a half months on average.
Two and a half months. NO-Cbl works differently. Vitamin B12 has a natural transport system in the body.
The blood-brain barrier has receptors for it. The thinking is that NO-Cbl hitches a ride on that system, passes through the barrier, and then releases nitric oxide directly inside the tumor.
Nitric oxide is a gas. At high concentrations, it is toxic to cells. The trick is getting it to the right cells.
The study did not test on human patients. It is preclinical work.
That is a long way from a prescription. But for a disease where the median survival has not budged in decades, any compound that crosses the barrier and shows activity is a signal. A real signal.
The stakes are concrete. Every year, roughly 12,000 Americans are diagnosed with glioblastoma. Most will be dead within two years.
The five-year survival rate is below 5 percent. Those numbers have not changed since the 1970s.
Families facing this diagnosis are told to get their affairs in order. That is the blunt reality. A therapy that can reach the tumor through the blood-brain barrier changes the geometry of the fight.
It does not cure the disease. Not yet.
But it opens a door that has been locked. Other drugs that failed did so because they never got to the tumor. NO-Cbl appears to get there.
The study also looked at how NO-Cbl worked alongside other agents. Combination therapy is the standard approach in oncology. A single drug rarely does the job.
The early data suggests NO-Cbl does not interfere with other treatments. That is not nothing.
Bauer and his team have been working on this for years. The Cleveland Clinic, a major cancer center, is involved. The compound is not a random lab curiosity.
It is a modified vitamin. Vitamins have a safety profile.
That matters when you are talking about a drug that has to be given to patients whose brains are already under siege. Fifteen months. That is the clock.
Every day, families watch it tick. NO-Cbl is not a cure. It is not even a treatment yet.
But it is a compound that does what almost nothing else does. It crosses the barrier.
It hits the tumor. That is a step. For glioblastoma, a step is rare.
A step is something.
